A Phase 2b Study to Evaluate Eltrekibart in Adults with Moderate to Severe Hidradenitis Suppurativa
- Conditions
- Moderate to Severe Hidradenitis SuppurativaTherapeutic area: Diseases [C] - Immune System Diseases [C20]
- Registration Number
- CTIS2023-505608-43-00
- Lead Sponsor
- Eli Lilly & Co.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 317
1. Have a diagnosis of HS for at least 12 months. 2. Have HS lesions in at least 2 distinct anatomical regions. At least 1 of the lesions must be Hurley Stage II or III. 3. Have an (abscess plus inflammatory nodule) count of at least 5. 4. Agree to use topical antiseptics daily. 5. Had an inadequate response or intolerance to a 28-day course of oral antibiotics.
1. Have more than 20 draining fistulae. 2. Have had surgical treatment for HS in the last 4 weeks before randomization. 3. Have an active skin disease or condition, that could interfere with the assessment of HS. 4. Have a current or recent acute, active infection. 5. Are immunocompromised. 6. Have a history of chronic alcohol abuse, IV drug abuse, or other illicit drug abuse within 1 year before screening.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method